Board ReviewInternal medicinePathway

GI Cancer Progression Pathways for the Medicine Shelf: Colon, Barrett, H. pylori, Liver

The adenoma-carcinoma sequence, Barrett esophagus, the H. pylori cascade, cirrhosis to HCC and PSC, with the surveillance interval at each step.

Step 2 CK outlineGastrointestinal SystemHealth Maintenance/Disease PreventionFoundational Science ConceptsMedicineSurgery

An endoscopy suite with the scope coiled on its tower
AI-generated image
Contents
  1. The adenoma-carcinoma sequence
  2. The Barrett progression
  3. The Correa cascade: H. pylori to gastric cancer
  4. The cirrhosis-to-HCC pathway
  5. Clue in the stem, next best step
  6. Where students lose points
  7. Practice question
  8. 60-second recall
  9. Sources

On the medicine shelf, a GI cancer question rarely asks you to stage a tumor. It describes a patient somewhere on a known path to cancer (a polyp, a segment of Barrett esophagus, an H. pylori infection, cirrhosis) and asks what happens next: the surveillance interval, the test that catches progression, or the treatment that interrupts it. Know where the patient sits on the pathway and the answer follows.

The adenoma-carcinoma sequence

Most colorectal cancers follow this chromosomal instability pathway, usually over about 10 years. That decade is the reason screening works.

  1. Normal mucosaAPC loss starts the process
  2. Early adenomaAPC lost; crypts proliferate
  3. Larger adenomaKRAS mutation drives growth
  4. Advanced adenoma18q loss (DCC, SMAD4)
  5. CarcinomaTP53 loss allows invasion

A second route, the microsatellite instability pathway, runs through defective mismatch repair. About 15% of colorectal cancers are MSI-high, but most of those are sporadic (MLH1 promoter hypermethylation, often through sessile serrated lesions with BRAF mutations). Lynch syndrome, the germline form, causes about 3%.

PathwayKey genesClinical pictureWhat the exam wants
Sporadic adenoma-carcinomaAPC, KRAS, TP53Older adult, often left-sidedAverage-risk screening from age 45
Familial adenomatous polyposisGermline APCHundreds to thousands of polyps in adolescenceYearly endoscopy from about age 10 to 12; colectomy
Lynch syndromeMLH1, MSH2, MSH6, PMS2, EPCAMYoung patient, right-sided tumor, endometrial cancer in the familyColonoscopy every 1 to 2 years from age 20 to 25
Serrated pathwayBRAF, CpG island methylationFlat right-sided sessile serrated lesionsComplete removal; these are the lesions colonoscopy misses

For average-risk adults, the USPSTF recommends screening from 45 to 75 years, with selective screening from 76 to 85. Options include colonoscopy every 10 years, FIT every year, stool DNA-FIT every 1 to 3 years, and CT colonography or flexible sigmoidoscopy every 5 years. Any positive noninvasive test is followed by colonoscopy.

The Barrett progression

Chronic reflux replaces the squamous lining of the distal esophagus with intestinal-type columnar epithelium. Adenocarcinoma of the distal third is the end point.

  1. Chronic GERDAcid and bile injure squamous mucosa
  2. Barrett, no dysplasiaIntestinal metaplasia; PPI and surveillance
  3. Low-grade dysplasiaConfirm with an expert GI pathologist
  4. High-grade dysplasiaEndoscopic eradication therapy
  5. Esophageal cancerDistal third, glandular

The ACG suggests a single screening endoscopy for patients with chronic GERD plus three or more risk factors: male sex, age over 50, White race, smoking, obesity, or a first-degree relative with Barrett esophagus or esophageal adenocarcinoma. Surveillance for nondysplastic Barrett: every 5 years if the segment is under 3 cm, every 3 years if it is 3 cm or longer. Confirmed low-grade dysplasia: endoscopic eradication therapy is suggested, with yearly surveillance as an alternative. High-grade dysplasia: endoscopic resection of any visible lesion, then ablation. Esophagectomy is no longer the default answer for dysplasia.

Squamous cell carcinoma follows a different road: smoking, heavy alcohol use, achalasia and caustic injury, with tumors in the upper and middle esophagus.

The Correa cascade: H. pylori to gastric cancer

  1. H. pylori infectionChronic active gastritis
  2. Atrophic gastritisLoss of glands and acid
  3. Intestinal metaplasiaGoblet cells in the stomach
  4. DysplasiaPrecursor lesion
  5. Gastric cancerIntestinal type

H. pylori is also the cause of most gastric MALT lymphomas, and low-grade gastric MALT lymphoma often regresses with eradication alone. When susceptibility is unknown, the 2024 ACG guideline recommends 14 days of optimized bismuth quadruple therapy (PPI, bismuth, tetracycline, metronidazole) for treatment-naive patients. Clarithromycin triple therapy is used only when the strain is known to be clarithromycin-susceptible. Confirm eradication at least 4 weeks after treatment with a urea breath test, stool antigen or biopsy, after holding the PPI for 2 weeks.

The cirrhosis-to-HCC pathway

  1. Chronic liver injuryHBV, HCV, alcohol, MASLD
  2. CirrhosisRegenerative nodules and fibrosis
  3. Dysplastic nodulePremalignant
  4. Hepatocellular carcinomaArterial enhancement, washout

Hepatitis B can cause HCC without cirrhosis, so selected noncirrhotic HBV carriers are screened too. AASLD recommends surveillance with ultrasound, with or without AFP, every 6 months in cirrhosis. A new nodule of 1 cm or more goes to multiphase CT or MRI; arterial-phase hyperenhancement with washout in a cirrhotic liver is diagnostic, so a biopsy is not needed.

Primary sclerosing cholangitis is the biliary version of this story. It carries risk of cholangiocarcinoma, gallbladder cancer and, with coexisting inflammatory bowel disease, colorectal cancer. AASLD guidance: MRI with MRCP, with or without CA 19-9, every year, and colonoscopy every year in patients who also have IBD.

Clue in the stem, next best step

Clue in the stemWhat it points toNext best step
Positive FIT in a 52-year-oldPossible advanced adenoma or cancerColonoscopy
Colon cancer at 38, mother with endometrial cancer at 45Lynch syndromeTumor MMR or MSI testing, genetic counseling, colonoscopy every 1 to 2 years for relatives at risk
Teenager with hundreds of colonic polypsFamilial adenomatous polyposisGenetic testing; plan prophylactic colectomy
4 cm Barrett segment, no dysplasiaLong-segment nondysplastic BarrettPPI and surveillance endoscopy in 3 years
Barrett with high-grade dysplasiaOne step from cancerEndoscopic resection and ablation
Dyspepsia, positive stool antigen, no prior treatmentH. pylori14 days of bismuth quadruple therapy, then confirm eradication
Low-grade gastric MALT lymphoma, H. pylori positiveAntigen-driven lymphomaEradicate H. pylori
Cirrhosis, new 2 cm nodule with arterial enhancement and washoutHepatocellular carcinomaDiagnosis made on imaging; stage and treat, no biopsy needed
Ulcerative colitis, rising alkaline phosphatase, beaded ducts on MRCPPrimary sclerosing cholangitisYearly MRCP and yearly colonoscopy

Where students lose points

  • Calling every MSI-high tumor Lynch syndrome. Most are sporadic; Lynch syndrome accounts for about 3% of colorectal cancers.
  • Sending Barrett with dysplasia to esophagectomy. Endoscopic eradication therapy is first-line for dysplasia and many early cancers.
  • Repeating endoscopy for nondysplastic Barrett every year. The interval is 3 or 5 years, set by segment length.
  • Choosing clarithromycin triple therapy without knowing susceptibility. Bismuth quadruple therapy is the default first-line regimen.
  • Skipping the eradication test after H. pylori treatment, or testing while the patient is still on a PPI.
  • Biopsying a classic HCC on multiphase imaging. In cirrhosis, the imaging pattern is enough.
  • Forgetting the colon in PSC. With coexisting IBD, colorectal cancer surveillance is yearly.

Practice question

A 58-year-old man comes to the office to discuss the results of an upper endoscopy. He has had heartburn several times a week for 15 years and takes omeprazole daily. He smokes 1 pack of cigarettes daily and has a BMI of 33 kg/m². Endoscopy showed salmon-colored mucosa extending 4 cm above the gastroesophageal junction, with no nodules or ulceration. Biopsies show intestinal metaplasia with goblet cells and no dysplasia.

In addition to continuing the proton pump inhibitor, which of the following is the most appropriate management?

  1. Repeat endoscopy in 6 months
  2. Repeat endoscopy in 3 years
  3. Repeat endoscopy in 5 years
  4. Radiofrequency ablation
  5. Esophagectomy
Show the answer

Answer: B. He has nondysplastic Barrett esophagus with a segment of 3 cm or longer. The ACG recommends surveillance endoscopy every 3 years for this group, along with long-term acid suppression.

Why the others are wrong. A: a short interval is used to recheck indefinite or newly found dysplasia, not nondysplastic Barrett. C: 5 years is the interval for segments shorter than 3 cm. D: ablation is for confirmed dysplasia, not nondysplastic Barrett. E: esophagectomy is reserved for cancers that cannot be managed endoscopically.

60-second recall

Say each answer out loud before you reveal it, then mark yourself. Retrieval, not rereading, is what makes it stick.

  1. 1Adenoma-carcinoma sequence
    APC, then KRAS, then 18q (DCC, SMAD4), then TP53.
    Did you get it?
  2. 2Average-risk colorectal screening
    Ages 45 to 75; colonoscopy every 10 years or FIT yearly.
    Did you get it?
  3. 3Lynch surveillance
    Colonoscopy every 1 to 2 years from age 20 to 25.
    Did you get it?
  4. 4Nondysplastic Barrett
    Every 5 years if under 3 cm, every 3 years if 3 cm or longer.
    Did you get it?
  5. 5H. pylori first-line
    Bismuth quadruple therapy for 14 days, then confirm eradication.
    Did you get it?
  6. 6HCC surveillance in cirrhosis
    Ultrasound with or without AFP every 6 months.
    Did you get it?

Next: browse every Board Review post, review GI cancers by organ, or see MedRise for students.

Sources

  1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell, 1990 (PubMed 2188735)
  2. US Preventive Services Task Force. Colorectal cancer: screening. Final recommendation statement, 2021
  3. Syngal S, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol, 2015 (PubMed 25645574)
  4. Shaheen NJ, et al. Diagnosis and management of Barrett's esophagus: an updated ACG guideline. Am J Gastroenterol, 2022 (PubMed 35354777)
  5. Chey WD, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol, 2024 (PubMed 39626064)
  6. Singal AG, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology, 2023 (PubMed 37199193)
  7. Bowlus CL, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology, 2023 (PubMed 36083140)

MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.

Learned something the hard way on a shelf or on the wards?

Write it up for MedRise Perspectives: 600 to 1,200 words, published under your name, with a decision usually within one day.

Book a free strategy call

Ten minutes to look at your exam date, your scores and what is getting in the way.